ClinicalTrials.gg
RecruitingNCT07320560CURE-AFUpdated Jan 6, 2026

Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping

An interventional study of Non-invasive mapping-guided ablation in Atrial Fibrillation (AF), sponsored by German Heart Institute. Recruiting at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by German Heart Institute · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 417 studies in Atrial Fibrillation with a site in Germany — 60 open to participants now, 88 under way, 4 of them phase 3. Atrial Fibrillation · Germany.

Planned enrollment
253rd of 284
45 · median 200
Started
2026
with 12 others
No phase
166 of 417
31 open now
Primary completion
2026-12
later than 30 of 87 live
Registered
402nd of 417
by date

Among the 417 studies in Atrial Fibrillation with a site in Germany, this one is the 253rd largest by planned enrollment of the 284 interventional ones that give a count, is one of 13 that started in 2026, is one of 166 with no phase, reaches primary completion later than 30 of the 87 other live ones, and was the 402nd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

60 of the 417 studies in Atrial Fibrillation with a site in Germany are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 417 studies in Atrial Fibrillation with a site in Germany, or all of them as a file.
02

Study summary

This pilot study investigates if non-invasive global mapping can guide catheter ablation of atrial fibrillation (AF) by defining personalized targets based on the temporal Stability of local Atrial High-Rate Activity (SAHRA). The study also assesses efficacy and safety of this approach and evaluates potential signals of harm. The main questions it aims to answer are:

  • Does ablation of targets defined by non-invasive global mapping improve rates of acute atrial fibrillation termination?
  • Does such a personalized ablation approach reduce arrhythmia recurrence rates? Researchers will compare the results of the personalized ablation approach with comparable patients that had undergone a conventional "empirical" ablation approach (pulmonary vein isolation).

Participants will:

  • Undergo a personalized catheter ablation approach employing both a non-invasive global mapping system and a conventional intracardiac mapping system
  • Visit the clinic 3, 6 and 12 months after ablation for clinical follow-up
  • Schedule a telephone visit 9 and 24 months after ablation for clinical follow-up
Read the detailed description

The aim of this study is to test the feasibility and potential of a personalized, non-invasive mapping-guided ablation approach in patients with persistent atrial fibrillation (AF), who are unlikely to benefit from empirical pulmonary vein isolation alone. As a pilot study, it is designed to assess feasibility and procedural efficacy as well as potential signals of harm.

General Strategy:

Patients with persistent AF planned for catheter ablation are eligible in case of left atrial enlargement.

The study intervention consists of two steps:

  1. Empirical pulmonary vein isolation in all patients (current standard of care).
  2. A personalized ablation approach targeting up to three additional atrial regions which harbour critical AF-perpetuating sources:

    • Target regions are selected based on the temporal Stability of local Atrial High-Rate Activity (SAHRA) using a non-invasive global mapping system (Acorys, Corify Care).
    • Selected target regions displaying stable high-rate activity are isolated or homogenized according to predefined regional borders based on the 15-segment bi-atrial model of the EHRA and EACVI Clinical Consensus on Standardized Atrial Regionalization.
03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • Atrial Fibrillation
  • Catheter Ablation
  • Non-invasive mapping
  • Global Mapping
  • Electrocardiographic Imaging
  • Body Surface Mapping
  • Atrial fibrillation drivers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Ablation-naïve patients with:

  1. Persistent AF planned for catheter ablation plus
  2. Left atrial enlargement (LA diameter ≥45 mm or LA volume index ≥35ml/m2 or LA area ≥20 cm2)

Exclusion criteria

Exclusion Criteria:

  • Previous cardiac ablation
  • Age \<18 years
  • Pregnancy or lactation
  • Previous stroke/
  • Severe left ventricular dysfunction ( \<35%)
  • Renal failure ( \<30 ml/min)
  • Dermal disease or predisposing for skin irritation or exanthema
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Non-invasive mapping-guided ablation

    In this arm patients undergo a personalized ablation approach: In addition to conventional pulmonary vein isolation, additional target regions will be ablated based on non-invasive global mapping.

    Procedure: Non-invasive mapping-guided ablation

Interventions

  • ProcedureNon-invasive mapping-guided ablation

    The study intervention consists of 1. Empirical pulmonary vein isolation (current standard of care) plus 2. A personalized ablation approach targeting up to three additional atrial regions which harbour critical AF-perpetuating sources: * Target regions are selected based on the temporal Stability of local Atrial High-Rate Activity (SAHRA) using a non-invasive global mapping system (Acorys, Corify Care). Local high-rate activity is confirmed by endocardial mapping. * Selected target regions displaying stable high-rate activity are isolated or homogenized according to predefined regional borders based on the 15-segment bi-atrial model of the EHRA and EACVI Clinical Consensus on Standardized Atrial Regionalization (Althoff et al. 2025).

06

What researchers measure

Primary outcomes

  1. Rate of acute AF termination

    Acute AF termination (to sinus rhythm or conversion into an organized atrial tachycardia) upon ablation

    Time frame: Procedural

Secondary outcomes

  1. Proportion of patients with arrhythmia-free survival

    Absence of any atrial tachyarrhythmia (atrial fibrillation \[AF\], atrial flutter \[AFL\] or atrial tachycardia \[AT\]) between days 91 and 365 post ablation. AF, AFL or AT will qualify as a recurrence after ablation if it lasts 30 s or longer.

    Time frame: Days 91 to 365 post-ablation

  2. Proportion of patients with AF-free survival

    Absence of atrial fibrillation \[AF\] between days 91 and 365 post ablation. AF will qualify as a recurrence after ablation if it lasts 30 s or longer.

    Time frame: Days 91 to 365 post-ablation

  3. Time to arrhythmia recurrence

    Time to first atrial tachyarrhythmia (atrial fibrillation \[AF\], atrial flutter \[AFL\] or atrial tachycardia \[AT\]) between days 91 and 365 post ablation. AF, AFL or AT will qualify as a recurrence after ablation if it lasts 30 s or longer.

    Time frame: Days 91 to 365 post-ablation

  4. Time to AF recurrence

    Time to first atrial fibrillation \[AF\] between days 91 and 365 post ablation. AF will qualify as a recurrence after ablation if it lasts 30 s or longer.

    Time frame: Days 91 to 365 post-ablation

  5. Rate of procedure-related complications

    Composite safety endpoint composed of: * cardiac tamponade requiring drainage * persistent phrenic nerve palsy lasting \>24 hours * serious vascular complications requiring intervention * stroke/TIA * atrioesophageal fistula * death

    Time frame: Day 0 to 30 post-ablation

Other outcomes

  1. Procedure time

    Skin-to-skin duration of the ablation (procedural endpoint)

    Time frame: Day 0

  2. Total left atrium indwelling time

    Procedural endpoint

    Time frame: Day 0

  3. Fluoroscopy time

    Procedural endpoint

    Time frame: Day 0

  4. Hemolysis marker levels on day 1 post-ablation

    Procedural endpoint

    Time frame: Day 1 post-ablation

  5. GFR on day 1 post-ablation

    Procedural endpoint

    Time frame: Day 1 post-ablation

  6. Proportion of patients with acute renal failure

    Procedural endpoint

    Time frame: Day 0 to 30 post-ablation

  7. hsTroponin on day 1 post-ablation

    Procedural endpoint

    Time frame: Day 1 post-ablation

07

Study locations

1 of 5 sites recruiting
  • German Heart Center of the Charité, Charité University Hospital Berlin
    Berlin, 10117, Germany
    Recruiting
  • Frankfurt University Heart and Vascular Center
    Frankfurt am Main, 60598, Germany
    Not yet recruiting
  • Central Lisbon University Hospital Centre (CHULC), Hospital de Santa Marta
    Lisbon, 1169-024, Portugal
    Not yet recruiting
    • Mario Martins Oliveira, M.D. · Contactm.martinsoliveira@gmail.com · 0035 121 3594000
    • Mario Martins Oliveira, M.D. · Principal investigator
  • Hospital Clinic, University of Barcelona
    Barcelona, 08036, Spain
    Not yet recruiting
    • Ivo Roca-Luque, M.D. Ph.D. · Contactiroca@clinic.cat · 0034 93 2271778
    • Ivo Roca-Luque, M.D. · Principal investigator
  • Gregorio Marañón General University Hospital
    Madrid, 28007, Spain
    Not yet recruiting
08

References and documents

Publications

  • Invers-Rubio E, Hernandez-Romero I, Reventos-Presmanes J, Ferro E, Guichard JB, Regany-Closa M, Pellicer-Sendra B, Borras R, Prat-Gonzalez S, Tolosana JM, Porta-Sanchez A, Arbelo E, Guasch E, Sitges M, Brugada J, Guillem MS, Roca-Luque I, Climent AM, Mont L, Althoff TF. Regional conduction velocities determined by noninvasive mapping are associated with arrhythmia-free survival after atrial fibrillation ablation. Heart Rhythm. 2024 Sep;21(9):1570-1580. doi: 10.1016/j.hrthm.2024.04.063. Epub 2024 Apr 16. PubMed 38636930 ↗
  • Althoff TF, Anderson RH, Goetz C, Petersen SE, Diaz PM, Nijveldt R, Maurovich-Horvat P, Bax J, Hussain S, Schmidt C, Spicer DE, Sanchez-Quintana D, Corsi C, Dossel O, Climent AM, Rodriguez B, Schotten U, Loewe A, Guillem MS, Cabrera JA, Merino JL, Wijnmaalen AP, Bertrand PB, de Groot N, Derval N, Didenko M, Donal E, Dweck MR, Ho SY. Regionalization of the atria for 3D electroanatomical mapping, cardiac imaging, and computational modelling: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Cardiovascular Imaging of the ESC. Europace. 2025 Jul 1;27(7):euaf134. doi: 10.1093/europace/euaf134. PubMed 40736086 ↗

Individual participant data

Plan to share: No — Data underlying published results will be provided upon reasonable request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 11 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Jan 6, 2026
StartEst.
Jan 15, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07320560
Lead sponsor
German Heart Institute
Responsible party
Till Althoff (Head of Research and Principal Investigator, German Heart Institute) — Principal investigator
First posted
Jan 6, 2026
Start date
Jan 15, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 6, 2026

Study contacts

Till F Althoff, M.D.
Contact
till.althoff@dhzc-charite.de
0049 30 450613163
Gerhard Hindricks, M.D.
Contact
gerhard.hindricks@dhzc-charite.de
030450613163
Till F Althoff, M.D.
principal investigator · German Heart Center of the Charitè, Berlin, Department of Cardiology, Angiology and Intensive Care Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion